Allogene Therapeutics

Off-the-shelf allogeneic CAR-T cell therapies for cancer.

PublicSouth San Francisco, CAFounded 2018

About

Allogene Therapeutics is developing allogeneic (off-the-shelf) CAR-T cell therapies derived from healthy donors rather than individual patients. This approach aims to make CAR-T therapy more accessible, scalable, and affordable than autologous approaches. The company has a pipeline targeting blood cancers and is exploring solid tumor applications.

Total Funding

$600M

Key Product

ALLO-501A allogeneic anti-CD19 CAR-T therapy

Geography

North America